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The majority of patients with non-small cell lung cancer present at the time of diagnosis
with stage IV metastatic disease and they experience 2 or more disease-related symp-
toms. These symptoms may have a negative impact on their health-related quality of life
(HR QOL). Data has shown many of these patients prefer a therapy to improve their symp-
toms rather than receive a therapy which slightly prolongs their survival without improving
their symptoms. The improvement of disease-related symptoms on a specific drug or reg-
imen augments the significance of prolongation of the progression-free survival or the
response rate as well as symptom worsening. The choice of the questionnaires to evalu-
ate patients’ reported outcomes and HR QOL benefits and the methods of collecting the
data and their interpretations are very important. Only if the data are collected and analyzed
properly will they be meaningful and can then be viewed as components that add the total
value to a treatment and provide a comprehensive picture of the benefits and risks of a
certain anticancer therapy.
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INTRODUCTION
Lung cancer is the leading cause of cancer death worldwide for
both men and women (1). A majority of these patients present at
the time of diagnosis with metastatic disease. Approximately 90%
of patients with advanced non-small cell lung cancer (NSCLC)
experience two or more disease-related symptoms such as cough,
dyspnea, pain, anorexia, or fatigue (2). These symptoms in turn
can cause psychological distress and may have a negative impact
on a patient’s health-related quality of life (HR QOL). High
degrees of psychological distress influence the emotional well-
being in both patients and their families. In one survey, 68% of
patients preferred a therapy that would improve disease-related
symptoms without prolonging their life as opposed to treat-
ment(s) that slightly prolonged their survival without improving
symptoms (3).
A patient’s well-being can be affected both through symptom-
control, treatment-related toxicity, and treatment efficacy. There-
fore, treatments which can decrease the tumor burden and growth,
and be less toxic, are very important for patients with advanced
NSCLC (4, 5). It is of the utmost importance for these patients to
preserve their independence and not be dependent on their loved
ones feeling like a burden at the end of their lives (6–8).
Some studies suggest a link between tumor response and
improvement of symptoms such as cough, dyspnea, chest pain, and
also systemic symptoms such as fever, anorexia, and weight loss (9–
11). The improvements in symptoms further augment the signifi-
cance of good response rates or prolonged PFS. As the median OS
of most of the patients with metastatic NSCLC is modest (around
1 year), with specific new targeted agents it approaches 2 years,
therefore HR QOL and patients’ reported outcomes (PROs) carry
high importance and thus will be reviewed here.
COLLECTION OF THE DATA
Patients’ reported outcomes and HR QOL benefits are usually
assessed during clinical trials using the self-administered cancer-
specific European Organization for Research and Treatment of
Cancer (EORTC) questionnaires QLQ C30 (12), the lung cancer-
specific EORTC QLQ LC13 (13), and the Euro QOL EQ-5D (14)
questionnaire (in afatinib LUX LUNG phase 3 trials or crizotinib
phase 3 trials) or functional assessment of cancer therapy-lung
(FACT-L) (15) (functional assessment of cancer treatment in lung
cancer) questionnaire (i.e., in IPASS phase 3 trial with gefitinib).
The QLQ C30 questionnaire consists of five functional scales
(physical, role, cognitive, emotional, and social functioning), three
symptom scales (fatigue, pain, and nausea/vomiting), a global
health status/QOL scale, and single items, i.e., dyspnea, loss of
appetite, constipation, diarrhea, sleep disturbance, and financial
impact. The QLQ LC13 questionnaire incorporates one multi-item
scale to assess dyspnea and a series of single items assessing cough,
pain, sore mouth, dysphagia, peripheral neuropathy, alopecia, and
use of pain medication.
For each scale/item, a linear transformation is applied to stan-
dardize the raw score on a range from 0 to 100 with 100 represent-
ing the best possible function/QOL for functional scales, and the
highest burden of symptoms for symptom scales and symptom
items. A 10-point change in an item or domain is perceived to be
clinically meaningful (16). The percentage of patients who are clas-
sified as improved (≥10-point increase for functioning scales and
≥10-point reduction for symptom domains or items from baseline
scores) with respect to each of the questionnaires is examined (16).
In addition, the time-to-deterioration of an item/domain score is
defined as the item from randomization to the first appearance of
a score that is 10 points or more lower or higher than the baseline
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score (≥10-point reduction for functioning scales and ≥10-point
increase for symptom scales or items).
The EQ-5D is a disease-generic questionnaire that comprises
the EQ-5D and EQ-visual analog scale (VAS). The EQ-5D mea-
sures five dimensions of health (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression). Each dimension com-
prises three levels (no problems, some/moderate problems, and
extreme problems). Utility scores range from 0 to 1 and are
calculated from the five EQ-5D items scores using the United King-
dom preference weights (17). The EQ-VAS records the patient’s
self-rated health status on a vertical, graduated (0–100) VAS.
Functional assessment of cancer therapy-lung questionnaire
(version 4) comprises 36 items across 5 domains/categories: phys-
ical, social, family, emotional, and functional well-being. The Lung
cancer subscale consists of symptoms, cognitive function, and
regret of smoking. Scores range from 0 (not at all) to 4 (very
much) (15).
Each protocol specifies a schedule for questionnaires to be com-
pleted (at baseline, every 2–4 weeks, at the end of the treatment
visit, and during the first follow-up visit). The use of concomi-
tant medications is assessed at the baseline and during the trial,
especially analgesic use, anti-anxiety/depression medications, O2
use, etc.
INTERPRETATION OF THE RESULTS
Patients must answer the questionnaires prior to learning the
results of their tests (scans) from their physicians in order to obtain
reliable results. Help with the questionnaires should be available
by knowledgeable staff in the clinic or hospital. Since patients
must fill out the questionnaire by themselves, supervision of this
procedure in order to ensure objectivity is important. Attention
should be paid to the baseline scores. In randomized trials, are
they well-balanced? Are they low (i.e., low burden of symptoms)
or high (i.e., high burden of symptoms)? If the baseline scores are
low, the percentage of patients with improved symptoms on cer-
tain anticancer treatments might be difficult to find. Delay of the
symptom deterioration is usually of high importance. The longi-
tudinal analysis which looks at symptoms and HR QOL over time
(at different visit intervals) might be informative.
The compliance of patients a propos to the completion of their
questionnaires must be reported at the baseline and also during the
study. The compliance during the study should remain at≥80% in
order to interpret the results appropriately. In the case of EORTC
questionnaires, both EORTC QLQ LC13 and QLQ C30 have to be
analyzed to get a complete picture not only of lung cancer-related
symptoms, but also of symptoms related to cancer treatment tox-
icities. The patients’ symptoms are treated by analgesics, cough
suppressants, O2, anti-depressants, appetite stimulating agents,
etc., and they all have to be incorporated in the final analysis.
Other factors such as patient’s performance status (improving or
deteriorating), weight loss, and special emotional counseling are
of great value and can influence patients’ HR QOL.
CONCLUSION
Patients’ reported outcomes and health-related quality of life out-
comes are important parameters of the evaluation of new drugs
or regimens of patients in advanced NSCLC, but only if the data
are collected and analyzed correctly. They should be viewed as
components of the total value of a treatment. They should pro-
vide, together with the other primary and secondary endpoints,
a comprehensive picture of the benefits and risks of anticancer
therapies for patients with metastatic NSCLC. This is the position
taken by the Food and Drug Administration (18) and the European
Medicine Agency (19, 20).
Dedicated personnel are required for this time-consuming
process of collecting and analyzing the PROs and HR QOL data.
The delivery of reliable results from these questionnaires requires
the team work of knowledgeable and devoted workers. Conse-
quently enabling patients with advanced NSCLC to feel more
comfortable and independent during the last months or years of
their life becomes a very important task in their treatment.
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